Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: Development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology
Kai Temming*, Marie Lacombe, Paul van der Hoeven, Jai Prakash, Teresa Gonzalo, Eli C.F. Dijkers, László Orfi, Gyorgy Kéri, Klaas Poelstra, Grietje Molema, Robbert J. Kok
*Corresponding author for this work
Research output: Contribution to journal › Article › Academic › peer-review
Dive into the research topics of 'Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: Development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology'. Together they form a unique fingerprint.